Lan Xiao

Hefei, 230031, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Co-encapsulated Ce6 + CpG and biopeptide-modified liposomes for enhanced transdermal photo-immunotherapy of superficial tumors.

Co-encapsulated Ce6 + CpG and biopeptide-modified liposomes for enhanced transdermal photo-immunotherapy of superficial tumors.

Journal: Materials today. Bio
Published: October 18, 2024

A self-gelling hemostatic powder boosting radiotherapy-elicited NK cell immunity to combat postoperative hepatocellular carcinoma relapse.

A self-gelling hemostatic powder boosting radiotherapy-elicited NK cell immunity to combat postoperative hepatocellular carcinoma relapse.

Journal: Biomaterials
Published: August 11, 2024

Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.

Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.

Journal: Gynecologic and obstetric investigation
Published: January 12, 2024

The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells.

The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells.

Journal: Journal of ovarian research
Published: March 01, 2023

Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.

Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.

Journal: BMC cancer
Published: October 14, 2022

Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.

Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.

Journal: Cancer medicine
Published: November 18, 2021

Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.

Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.

Journal: Journal of gynecologic oncology
Published: February 15, 2021

Expert consensus on the management process of gynecological emergency under the regular epidemic prevention and control of COVID-19.

Expert consensus on the management process of gynecological emergency under the regular epidemic prevention and control of COVID-19.

Journal: Gynecology and obstetrics clinical medicine
Published: January 31, 2021

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer.

Journal: BMC molecular and cell biology
Published: May 15, 2019

A case report for severe hand-foot skin reaction caused by chemotherapy with actinomycin D in a patient with oculocutaneous albinism.

A case report for severe hand-foot skin reaction caused by chemotherapy with actinomycin D in a patient with oculocutaneous albinism.

Journal: OncoTargets and therapy
Published: March 19, 2019

miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells.

miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells.

Journal: Frontiers in genetics
Published: May 02, 2018

YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells.

YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells.

Journal: OncoTargets and therapy
Published: April 14, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026